What determines the natural history of recurrent hepatitis C after liver transplantation?

Journal of Hepatology

Volumn 42, Issue 4, 2005, Pages 448-456

  Berenguer, Marina ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; STEROID; TACROLIMUS;

ALCOHOL CONSUMPTION; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; HEPATITIS C; HUMAN; IMMUNOGENICITY; LIVER TRANSPLANTATION; MORTALITY; ORGAN DONOR; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD;

EID: 14844293468     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2005.01.011     Document Type: Review

References (45)

1. M. Berenguer, F.X. Lopez-Labrador, and T.L. Wright Hepatitis C and liver transplantation J Hepatol 35 2001 666 678
2. R.H. Wiesner, M. Sorrell, and F. Villamil Report of the first international liver transplant society consensus conference on liver transplantation and hepatitis C Liver Transpl 9 2003 S1 S9
3. E. Gane The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients Liver Transpl 9 2003 S28 S34
4. G.W. McCaughan, and A. Zekry Mechanisms of HCV reinfection and allograft damage after liver transplantation J Hepatol 40 2004 368 374
5. M. Berenguer, L. Ferrell, J. Watson, M. Prieto, M. Kim, and M. Rayón HCV-related fibrosis progression following liver transplantation: increase in recent years J Hepatol 32 2000 673 684
6. M. Berenguer, V. Aguilera, M. Prieto, D. Carrasco, M. Rayón, and F. San-Juan Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern? Liver Transpl 2003 1152 1158
7. U.P. Neumann, T. Berg, M. Bahra, G. Puhl, O. Guckelberger, J.M. Langrehr, and P. Neuhaus Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up Transplantation 77 2004 226 231
8. M. Charlton Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence Liver Transpl 9 2003 S58 S62
9. M. Berenguer Host and donor pre- and post-liver transplant risk factors impacting on HCV recurrence Liver Transpl 9 2003 S44 S47
10. J.R. Lake The role of immunosuppression in recurrence of hepatitis C Liver Transpl 9 2003 S63 S66
11. M. Garcia-Retortillo, X. Forns, A. Feliu, E. Moitinho, J. Costa, and M. Navasa Hepatitis C virus kinetics during and immediately after liver transplantation Hepatology 35 2002 680 687
12. A. Zekry, M. Gleeson, S. Turhan, and G.W. McCaughan The effect of mycophenolate compared to azathioprine on viral load in HCV liver transplant recipients Liver Transpl 10 2004 52 58
13. K. Watashi, M. Hijikata, M. Hosaka, M. Yamagi, and K. Shimotohno Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes Hepatology 38 2003 1282 1288
14. J.R. Stangl, K.L. Carroll, M. Illichmann, and R. Striker Effect of antimetabolite immunosuppressants on flaviviridae, including hepatitis C virus Transplantation 77 2004 562 567
15. D.R. Nelson, C. Soldevila-Pico, A. Reed, M.F. Abdelmaleck, A.W. Hemming, and W.J. Van der Werf The effect of anti-interleukin-2 receptor therapy on the course of hepatitis C recurrence after liver transplantation Liver Transpl 7 2001 1064 1070
16. V. Di Martino, C. Brenot, D. Samuel, F. Saurini, V. Paradis, and M. Reynes Influence of liver hepatitis C virus RNA and hepatitis C virus genotype on Fas-mediated apoptosis after liver transplantation for hepatitis C Transplantation 70 2000 1390 1396
17. M. Gigou, A.M. Roque-Alfonso, B. Falissard, F. Penin, E. Dussaix, and C. Feray Genetic clustering of hepatitis C virus strains and severity of recurrent hepatitis after liver transplantation J Virol 75 2001 11292 11297
18. F.X. Lopez-Labrador, M. Berenguer, A. Sempere, M. Prieto, R. Sirera, and A. Gonzalez-Molina Genetic variability of hepatitis C virus NS3 protein in human leukocyte antigen-A2 liver transplant recipients with recurrent hepatitis C Liver Transpl 10 2004 217 227
19. J.I. Arenas, J.F. Gallegos-Orozco, T. Laskus, J. Wilkinson, A. Khatib, and C. Fasola Hepatitis C quasi-species dynamics predict progression of fibrosis after liver transplantation JID 189 2004 2037 2046
20. J.D. Eason, S. Nair, A.J. Cohen, J.L. Blazek, and G.E. Loss Jr Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy Transplantation 75 2003 1396 1399
21. S. Brillanti, M. Vivarelli, N. De Ruvo, A. Abdiueli, V. Camaggi, and A. D'Errico Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation Liver Transpl 8 2002 884 888
22. M. Berenguer, J. Crippin, R. Gish, N. Bass, A. Bostrom, and G. Netto A model to predict severe HCV-related disease following liver transplantation Hepatology 38 2003 34 41
23. A. Jain, R. Kashyap, A.J. Demetris, B. Eghstesad, R. Pokharna, and J.J. Fung A prospective randomized trial of Mycophenolate Mofetil in liver transplant recipients with hepatitis C Liver Transpl 8 2002 40 46
24. C.G. Fasola, G.J. Netto, L.L. Christensen, J. Rakela, and M. Thomas Lower incidence of early HCV RNA levels and HCV recurrence post-liver transplantation in patients induced with mycophenolate mofetil: a high-dose benefit Am J Transplant 2 2002 196
25. K.W. Burak, W.K. Kremers, K.P. Batts, R.H. Wiesner, C.B. Rosen, and R.R. Razonable Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C Liver Transpl 8 2002 362 369
26. P. Martin, R.W. Busuttil, R.M. Goldstein, J.S. Crippin, G.B. Klintmalm, W.E. Fitzsimmons, and C. Uleman Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis C: a prospective randomized trial Liver Transpl 10 2004 1258 1262
27. J. Hunt, F.D. Gordon, W.D. Lewis, E. Pomfret, J.J. Pomposelli, R.L. Jenkins, and U. Khettry Histological recurrence and progresión of hepatitis C after orthotopic liver transplantation: influence of immunosuppressive regimens Liver Transpl 7 2001 1056 1063
28. A. Rimola, M.C. Londoño, G. Guevara, M. Bruguera, M. Navasa, and X. Forns Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation Transplantation 78 2004 686 691
29. M. Berenguer, M. Prieto, F. San Juan, M. Rayón, F. Martinez, and D. Carrasco Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients Hepatology 36 2002 202 210
30. M. Wali, R.F. Harrison, P.J. Gow, and D. Mutimer Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C Gut 51 2002 248 252
31. V.I. Machicao, H. Bonatti, M. Krishna, B.A. Aqel, F.J. Lukens, and J.H. Nguyen Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C Transplantation 77 2004 84 92
32. P. Toniutto, C. Fabris, N. Bortolotti, R. Minisini, C. Avellini, E. Fumo, and M. Pirisi Evaluation of donor hepatic iron concentration as a factor of early fibrotic progression after liver transplantation J Hepatol 41 2004 307 311
33. H.R. Rosen, J.J. Lentz, S.L. Rose, J. Rabkin, C.L. Corless, K. Taylor, and S. Chou Donor polymorphism of tumor necrosis factor gene. Relationship with variable severity of hepatitis C recurrence after liver transplantation Transplantation 68 1999 1898 1902
34. J.I. Arenas, H.E. Vargas, and J. Rakela The use of hepatitis C-infected grafts in liver transplantation Liver Transpl 9 2003 48 51
35. P.W. Baron, D. Sindram, D. Higdon, D.N. Howell, M.R. Gottfried, J.E. Tuttle-Newhall, and P.A. Clavien Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation Liver Transpl 6 2000 407 412
36. C. Feray, M. Gigou, D. Samuel, B. Ducot, P. Maisonneuve, and M. Reynes Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation Ann Intern Med 128 1998 810 816
37. J. Neuberger, K.H. Schulz, C. Day, W. Fleig, G. Berlakovich, and M. Berenguer Transplantation for alcoholic liver disease J Hepatol 36 2002 130 137
38. M. Berenguer, M. Prieto, J.M. Rayón, J. Mora, M. Pastor, and V. Ortiz Natural history of clinically compensated HCV-related graft cirrhosis following liver transplantation Hepatology 32 2000 852 858
39. G. Testa, J.S. Crippin, G.J. Netto, R.M. Goldstein, L.W. Jennings, and B.S. Brkic Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients Liver Transpl 6 2000 553 561
40. Sugawara Y, Makuuchi M. Should living donor liver transplantation be offered to patients with hepatitis C virus cirrhosis? 2nd Forum in Liver Transplantation in J Hepatol 2005; April.
41. A. Mañez, R. Mateo, J. Tabasco, S. Kusne, T.E. Starzl, and R.J. Duquesnoy The influence of HLA donor-recipient compatibility of the recurrence of HBV And HCV hepatitis after liver transplantation Transplantation 59 1995 640 642
42. E.J. Gane, B.C. Portmann, N.V. Naoumov, H.M. Smith, J.A. Underhill, P.T. Donaldson, G. Maertens, and R. Williams Long-term outcome of hepatitis C infection after liver transplantation N Engl J Med 334 1996 815 820
43. H.E. Vargas, T. Laskus, L.F. Wang, M. Radkowski, A. Poutous, and R. Lee The influence of hepatitis C virus genotypes on the outcome of liver transplantation Liver Transpl Surg 4 1998 22 27
44. S.J. Cotler, L.K. Gaur, D.R. Gretch, M. Wile, D.M. Strong, and M.P. Bronner Donor-recipient sharing of HLA class II alleles predicts earlier recurrence and accelerated progression of hepatitis C following liver transplantation Tissue Antigens 52 1998 435 443
45. L.S. Belli, C. Zavaglia, A.B. Alberti, F. Poli, G. Rondinara, and E. Silini Influence of immunogenetic background on the outcome of recurrent hepatitis C after liver transplantation Hepatology 31 2000 1345 1350